The GLP-1 era didn't sneak up on anyone. It arrived loud, fast, and impossible to ignore.

Within two years, medications like Ozempic, Wegovy, and Mounjaro moved from primarily being discussed in diabetes care to dominating mainstream conversation. Celebrities stopped pretending their weight loss was "just eating clean." Doctors started prescribing weight loss drugs to patients they'd previously told to "just eat less and move more." And suddenly, millions of people were experiencing something they'd been chasing for decades: significant, sustained weight loss without relentless hunger.

The conversation shifted. For the first time in modern medicine, pharmaceutical intervention for obesity started to feel less like a failure of willpower and more like addressing a metabolic condition that had been undertreated for too long.

But here's what most people don't realize: we're still in the early stages. GLP-1s aren't the end of this story. They're the opening chapter.

The next wave of weight loss medications is already in development, and some are in late-stage clinical trials. These drugs don't just target one hormone receptor. They target two, three, sometimes four at once. They're showing weight loss outcomes that make current GLP-1s look modest. And they're forcing every professional in the wellness and healthcare space—including health coaches—to reckon with a new reality: pharmaceutical weight loss is here, it's evolving fast, and it's not going away.

The question isn't whether health coaches should care about this. It's how we position ourselves in a landscape where medication is becoming a standard part of weight management for millions of people.

For health coaches supporting clients with emotional eating alongside GLP-1 use, see our complete guide on GLP-1s and emotional eating.

Key Takeaways:

• GLP-1 receptor agonists (like Ozempic and Wegovy) transformed weight loss treatment, but they're just the beginning. Dual and triple agonist medications targeting multiple metabolic pathways are already in clinical trials and showing even more dramatic results.
  
  
• The next generation of weight loss drugs will likely target GLP-1 plus GIP, glucagon, amylin, or other hormone receptors simultaneously, potentially offering 20–25% body weight reduction compared to GLP-1's 15–20%.
  
  
• No matter how effective these medications become, they don't address the behavioral, emotional, and lifestyle patterns that determine long-term success. That's why health coaches aren't being replaced—they're becoming more essential.
  
  
• Health coaches working with clients on weight loss medications need to understand the evolving landscape without practicing outside their scope. We don't prescribe, dose, or manage medications. We support the lifestyle foundation that makes any intervention sustainable.
  
  
• IIN's updated curriculum includes comprehensive training on GLP-1 medications and metabolic health, preparing coaches to work confidently with clients navigating pharmaceutical interventions while maintaining professional boundaries.
  
  

What's Actually Coming (And It's Already Further Along Than You Think)

Let's talk about what's in the pipeline, because it's not speculative. It's concrete.

Dual Agonists: Two Hormones, Better Results

Tirzepatide (Mounjaro/Zepbound) is already FDA-approved and commercially available. It's a dual agonist: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The result? Weight loss averaging 20–22% of body weight in clinical trials—significantly more than GLP-1-only medications, which average 15–17%.

GIP affects insulin secretion, fat storage, and satiety in ways that complement GLP-1's effects. By targeting both pathways, tirzepatide produces stronger appetite suppression, better blood sugar control, and more substantial weight loss.

This is the current state of the market. But it's not the future. It's what's already here.

Triple Agonists: Adding Glucagon to the Mix

Retatrutide, developed by Eli Lilly, is a triple agonist. It targets GLP-1, GIP, and glucagon receptors. Early clinical trial data showed an average weight loss of 24% over 48 weeks. Some participants lost more than 30% of their body weight.

To put that in perspective: a person weighing 200 pounds could lose 48-60 pounds on a triple agonist, compared to 30–40 pounds on a GLP-1-only medication.

Retatrutide is currently in Phase 3 trials. If it clears FDA approval, it could be available within the next 1–2 years. That's not a distant future. That's the very near term.

Beyond Injectables: Oral Medications Are Coming

Most current GLP-1 and dual agonist drugs require weekly or daily injections, which is a barrier for some patients. But oral versions are in development. Rybelsus (oral semaglutide) is already FDA-approved for Type 2 diabetes, though its weight loss efficacy is lower than injectable versions.

Novo Nordisk and other companies are working on more potent oral formulations that could match injectable efficacy. If successful, this removes one of the last friction points for widespread adoption.

Next-Level Targets: Amylin, Leptin, and Combination Approaches

Other drugs in development are targeting amylin (which regulates appetite and gastric emptying), leptin (which signals energy balance and satiety), and other metabolic pathways. Some researchers are exploring combinations of medications that address multiple aspects of metabolic dysfunction simultaneously: appetite, energy expenditure, fat storage, insulin sensitivity, and inflammation.

The strategy is clear: stack mechanisms of action to produce outcomes that single-target drugs can't achieve.

This is the pharmaceutical equivalent of what integrative health has always understood: one intervention rarely solves a complex, multifactorial problem. You need to address the whole system.

What This Means for Clients (And Why Coaches Still Matter)

If current trends continue, triple agonists may receive FDA approval, oral versions could become available, insurance coverage may expand, and costs could decline. Weight loss medications may eventually become as normalized as statins or blood pressure medications.

Does that make health coaches irrelevant?

No. It makes us more necessary.

Here's why. Medications change appetite. They change blood sugar regulation. They change how the body stores and burns fat. But they don't change behavior. They don't rewire emotional eating patterns. They don't teach someone how to nourish their body adequately when hunger signals are muted. They don't address the relationship with food that developed over decades. They don't build the skills needed to maintain weight loss after the medication stops or loses efficacy.

And they definitely don't address the deeper questions clients are sitting with when they start these medications: Who am I if I'm not struggling with my weight? What happens if this doesn't work? What if it does work, and I still don't feel the way I thought I would?

These are not pharmacological questions. They're human questions. And they require the kind of support that medication alone cannot provide.

Every gastroenterologist, endocrinologist, and obesity medicine specialist prescribing these drugs will tell you the same thing: medication works best when paired with lifestyle intervention. Diet. Movement. Sleep. Stress management. Behavioral change. The problem is that most prescribers don't have the time, training, or infrastructure to provide that level of ongoing support.

That's the gap health coaches fill. Not as replacements for medical care. As partners in it.

What Health Coaches Can (And Can't) Do in This Space

Let's be very clear about scope of practice, because this is where the profession's credibility lives or dies.

What we cannot do:

• Prescribe, recommend, or advise on specific weight loss medications
• Dose medications or suggest dosage changes
• Diagnose metabolic conditions or determine medical eligibility for medications
• Manage side effects or tell clients whether to continue or stop a medication
• Position ourselves as medical experts or replacements for physician care

What we absolutely can do:

• Educate clients about the role of lifestyle factors in metabolic health
• Support adequate nutrition, especially protein intake, when appetite is suppressed
• Help clients navigate emotional eating patterns that don't disappear with medication
• Address stress, sleep, movement, and other primary food factors that affect outcomes
• Provide accountability, encouragement, and non-judgmental support through the process
• Help clients develop sustainable habits that support long-term maintenance
• Facilitate the conversation between what medication can do and what lifestyle must do

The most effective health coaches in this space don't see medication as competition. They see it as one tool in a larger strategy. And they position themselves as the professionals who help clients use that tool well while building the foundation that makes long-term success possible.

This is not about being anti-medication or pro-medication. It's about being pro-client and pro-sustainability.

The Constant: Behavior Change Support Will Always Matter

Here's what won't change, no matter how sophisticated weight loss drugs become: human beings are complex, emotional, relational creatures who don't operate like machines.

You can suppress appetite pharmacologically. You can increase insulin sensitivity. You can alter fat storage. But you can't medicate someone into a healthy relationship with food. You can't inject self-compassion. You can't dose stress management or prescribe purpose.

The clients walking into coaching sessions in 2026 and beyond will still be dealing with:

• Decades of internalized diet culture and body shame
• Emotional regulation strategies that have relied on food since childhood
• Disconnection from hunger and fullness cues that pre-dates any medication
• Fear of regaining weight if the medication stops working
• Identity shifts that come with dramatic physical changes
• Social and relational dynamics that complicate weight loss (unsupportive partners, jealous friends, workplace pressure)

These are not side effects. These are the actual human experience of navigating weight, health, and self-worth in a culture that has never been neutral about bodies.

Medication can make the weight loss easier. It cannot make the emotional, psychological, and behavioral work unnecessary. And that work is precisely what health coaches are trained to support.

IIN's approach to this is grounded in three principles that become even more relevant in a pharmaceutical era: primary food (nourishment beyond the plate), bio-individuality (what works for one person won't work for another), and multidimensional health (physical, mental, emotional, and spiritual wellness are interconnected).

These concepts don't compete with medication. They complete it.

How to Prepare Your Practice for an Evolving Landscape

If you're a health coach (or considering becoming one), here's how to position yourself for this shifting terrain.

1. Educate yourself on the science without pretending to be a clinician.

You don't need to be an expert on pharmacology. But you should understand the basics: how GLP-1s work, what dual and triple agonists do differently, common side effects, and why lifestyle support matters alongside medication.

This isn't so you can advise clients on medications. It's so you can have informed conversations, ask good questions, and know when to refer back to the prescribing physician.

2. Develop a neutral, non-judgmental stance.

Some coaches are philosophically opposed to weight loss medications. Some are enthusiastic supporters. Your personal opinion is irrelevant to your professional effectiveness.

The client in front of you gets to decide what tools they use. Your job is to support them in using those tools well, regardless of whether you would make the same choice.

Judgment—in either direction—destroys trust. And trust is the foundation of behavior change.

3. Specialize in what medications can't do.

Position your coaching around the things pharmaceutical intervention doesn't address: emotional eating, body image, sustainable habit formation, stress management, sleep optimization, identity work, and long-term maintenance strategies.

This isn't a niche. It's the majority of the work.

4. Build relationships with prescribers who value collaborative care.

The most forward-thinking physicians, endocrinologists, and obesity medicine specialists are actively looking for health coaches to partner with. They know their patients need more support than a 15-minute prescription visit can provide.

If you can demonstrate that you understand scope of practice, work collaboratively, and genuinely improve patient outcomes, you become a referral partner.

This is how integrative care actually works in practice.

5. Market to the need, not the method.

Don't position yourself as "the GLP-1 coach" or "the anti-medication coach." Position yourself as the coach who helps people navigate weight, health, and self-worth in a sustainable, compassionate way—whatever tools they're using.

Clients don't just care about your philosophy. They care about whether you can help them feel better, build healthier habits, and create lasting change. Learn more about what health coaches actually do in practice.

The Bigger Picture: What the Pharmaceutical Boom Reveals

Here's the uncomfortable truth that the weight loss medication boom has made impossible to ignore: for decades, we told people that obesity was a personal failing. A lack of discipline. A character flaw. We built an entire industry around shame, restriction, and the idea that if you just tried hard enough, you could willpower your way to thinness.

And then medications came along that produced 15–25% weight loss with relatively manageable side effects, and suddenly the narrative crumbled. Because if a weekly injection can do what decades of dieting, exercise, and "just eat less" couldn't, maybe the problem was never willpower. Maybe it was biology, hormones, metabolic dysregulation, and a food environment designed to override satiety signals.

The pharmaceutical approach isn't perfect. It has side effects. It's expensive. It doesn't work for everyone. And it still requires lifestyle support to be effective long-term.

But what it has done—and this matters—is shift the conversation away from moralizing weight and toward treating it as a complex, multifactorial health condition that deserves compassionate, evidence-based intervention.

Health coaches have always known this. We've been saying for years that shame doesn't work, that bio-individuality is real, that sustainable change requires addressing the whole person.

The medication era doesn't threaten that message. It validates it.And the coaches who understand this—who can hold space for clients using medication without judgment, who can provide the behavioral and emotional support that makes pharmaceutical intervention actually sustainable—are the ones who will thrive in the next decade of this profession.

 
Ready to Learn How to Support Clients in This Evolving Landscape?
IIN's Health Coach Training Program equips you with the knowledge, skills, and professional framework to work confidently with clients navigating weight loss—with or without medication. Talk to an admissions advisor to learn more.

Book a Free Consultation → 

IIN's Approach to Supporting Clients Using Weight Loss Medications
No judgment. No bias. Just compassionate, evidence-informed support for the whole person. IIN's 2026 curriculum includes training on GLP-1 medications, metabolic health, and how to coach clients navigating pharmaceutical interventions within scope of practice

Download the Free Curriculum Guide

Sources

[1] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.

[2] Jastreboff AM, et al. Triple–hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. 2023;389:514-526.

[3] Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002.

[4] Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385:503-515.

[5] FDA. Medications containing semaglutide marketed for type 2 diabetes or weight loss.

[6] American Society of Bariatric Physicians. Obesity medicine and pharmacotherapy guidelines.

[7] Garvey WT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016;22(Suppl 3):1-203.

[8] Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America. 2018;102(1):183-197.

This article is for informational purposes and does not constitute medical or dietary advice. Always consult a qualified healthcare provider for personalized medical guidance.